We have used Affymetrix gene chip technology to look for changes in gene expression caused by a 24 h exposure of rat primary neonatal cardiac myocytes to the cardioprotective agent urocortin. We observed a 2.5-fold down-regulation at both the mRNA and protein levels of a specific calcium-insensitive phospholipase A 2 enzyme. Levels of lysophosphatidylcholine, a toxic metabolite of phospholipase A 2 , were lowered by 30% in myocytes treated with urocortin for 24 h and by 50% with the irreversible iPLA 2 inhibitor bromoenol lactone compared with controls. Both 4 h ischemia and ischemia followed by 24 h reperfusion caused a significant increase in lysophosphatidylcholine concentration compared with controls. When these myocytes were pretreated with urocortin, the ischemia-induced increase in lysophosphatidylcholine concentration was significantly lowered. Moreover, co-incubation of cardiac myocytes with urocortin, or the specific phospholipase A 2 inhibitor bromoenol lactone, reduces the cytotoxicity produced by lysophosphatidylcholine or ischemia/reperfusion. Similarly, in the intact heart ex vivo we found that cardiac damage measured by infarct size was significantly increased when lysophoshatidylcholine was applied during ischemia, compared with ischemia alone, and that pre-treatment with both urocortin and bromoenol lactone reversed the increase in infarct size. This, to our knowledge, is the first study linking the cardioprotective effect of urocortin to a decrease in a specific enzyme protein and a subsequent decrease in the concentration of its cardiotoxic metabolite.
However, the protection conferred on myocytes by Ucn is lost in the presence of the protein synthesis inhibitor cyclohexamide (13) . Because the cardioprotective effect of Ucn requires altered protein synthesis, we have previously used Affymetrix gene chip technology to search for global gene changes associated with a 24 h exposure to Ucn in rat neonatal primary cardiac myocytes. The gene chip data showed that expression of several genes were altered (14) . For example Ucn caused an increase in the mRNA and protein levels of a specific K ATP channel subtype, Kir6.1 (14) . Furthermore, blockers of this channel enhanced cell death during ischemia/reperfusion, but channel openers were cardioprotective (14) . Although K ATP channels have a major role to play in Ucn induced cardioprotection, from the gene chip data, there may be other unknown mechanisms contributing to its overall cardioprotective effect.
We now report on a different gene, encoding a calcium-independent and bromoenol lactone (BEL)-sensitive phospholipase A 2 (iPLA 2 ), which was found to be down-regulated by Ucn on the same Affymetrix gene chip that showed an increase in K ATP channel gene expression (14) . Phospholipase A 2 , is a superfamily of esterases that hydrolyze the sn-2 ester bond in phospholipids, releasing free fatty acids, arachidonic acid (AA), and lyso metabolites principally lysophosphatidylcholine (LPC). Individual members of this family can be distinguished based on size, subcellular localization, substrate specificity, sensitivity to various blockers, and calcium dependency (15) . However, from this large family, only the major cardiac specific subtype, the BEL-sensitive and calcium-insensitive isoform iPLA 2 has been shown to increase its activity during ischemia/reperfusion, with a concomitant increase in its metabolites notably AA and LPC. This latter metabolite of iPLA 2 has been implicated in cell death during ischemia/reperfusion (16, 17) . We now report on the cardioprotective mechanism of Ucn in relation to the deleterious effect on cardiac cells of increased iPLA 2 activity and LPC concentration.
MATERIALS AND METHODS

Rat neonatal cardiac myocyte preparation
Hearts were removed from 2-day-old Sprague Dawley rats, and ventricular myocytes were isolated as described previously (3). Cells were untreated or exposed to Ucn (10 −8 mol/L), LPC (10 −6 mol/L), and BEL (10 −6 mol/L) as indicated or were subjected to ischemia or ischemia plus reperfusion under the conditions described by Brar et al (8) before analysis.
RNA isolation
Total RNA was isolated by using an RNA isolator solution TRIZol (Gibco BRL). RNA pellets were resuspended in diethylpyrocarbonate-treated water at a concentration of 1 µg/µl.
Affymetrix gene chip analysis
Elsewhere, we have described in detail the methodology and gene chips used (14) .
RT-PCR
First-strand synthesis
Total RNA derived from control and Ucn-treated primary cardiac myocytes was treated for 30 min with 1 unit of RQ1 RNase free DNase (Promega). The RNA was extracted with phenol/chloroform and resuspended to a final concentration of 1 µg/µl. RNA (2 µg) was then combined with an oligo dT primer and added to a 20 µl first-strand cDNA synthesis reaction containing 18 units of AMV reverse transcriptase (Promega) and was incubated for 45 min at 42°C. The reaction was terminated by incubation at 94°C for 3 min and then stored at -20°C until use.
PCR
The following primers were used to semiquantitate transcript levels of iPLA 2 and a housekeeping gene, cyclophilin, from the gene chip data.
Rat cyclophilin
Forward primer: 5′ CGAGCTGTTTGCAGACAAAG 3′
Reverse primer: 5′ TTCTTGCTGGTCTTGCCATT 3′
Rat iPLA 2 Forward primer: 5′ GCGGCAGAAACTGTAAAAGC 3′
Reverse primer: 5′ TGATAGGCCCCTGTGAAAACT 3′
RNA slot blots
DNase (5 µg)-treated total RNA from control and Ucn-treated myocytes was applied to a hybond N + membrane by using a slot blotter. The membrane was prehybridized for 2 h in Denhardt's containing hybridization solution. The PCR products from the RT-PCR reactions of iPLA 2 and cyclophilin were random primed, labeled with 32 P dUTP, and used as probes in an overnight hybridization at 65°C. Membranes were washed 2× in 1 × SSC 0.1% SDS at the hybridization temperature and exposed to X-ray film overnight.
Western blots
Control and Ucn-treated myocytes (2×10 6 per well) were washed in sterile phosphate buffered saline (PBS). Gel loading buffer (100 µl) was applied to each well of a sixwell plate. Cells were scraped in this buffer, removed into an Eppendorf tube, and boiled for 5 min prior to gel loading. SDS polyacrylamide gels (12%) were run at 40 mV. Proteins were transferred overnight onto hybond C membranes. The membranes were blocked for 2 h in 4% Marvel 1× PBS. Blocked membranes were incubated with a primary antibody against iPLA 2 (Insight Biotechnology, London, UK) or actin (Santa Cruz, CA) for another 2 h. These were removed, and the membranes were washed in 1× PBS Tween two times for 5 min before application of the relevant secondary antibody for 1 h. Secondary antibodies were removed and the membranes were washed several times in 1× PBS Tween prior to application of enhanced chemiluminescence reagent (Amersham Pharmacia Biotech, Little Chalfont, UK) and autoradiography.
Measurement of lysophosphatidylcholine
Cultures of primary cardiac myocytes were labeled with 3 H-choline for 48 h alone, or in the presence of Ucn (10 −8 mol/L) for 24 h or BEL (10 −6 mol/L) for 24 h before harvesting. Other cells were exposed to 4 h ischemia or 4 h ischemia followed by 24 h reperfusion either alone or after a pretreatment with Ucn for 24 h prior to exposure to ischemia. Cells were washed twice with icecold phosphate buffered saline to remove unincorporated label and then harvested in 0.5 ml of 0.5% saline and sonicated at full power for 10 min.
Sonicated cells were centrifuged for 10 min at 13,000 × g. The supernatant was removed for protein measurement. The pelleted cells were resuspended in 1 ml of chloroform/methanol (1:1) and sonicated again for 10 min at full power. Chloroform/water (1 mL; 1:1) was added. The mixture was vortexed and the phases separated by centrifugation at 1000 x g for 10 min. The top layer was discarded and the lower layer was removed, vacuum dried, and resuspended in 20 µl of methanol. Half of this resuspended lipid was loaded onto a thin-layer chromatography plate and run in a solvent consisting of chloroform, methanol, acetic acid, and water in a ratio of 60:40:6:0.6.
Phosphatidylcholine (PC) and lysophosphatidylcholine (LPC) standards were run alongside the radiolabeled samples as migration markers. These standards were stained and visualized by using anisaldehyde. The radiolabeled samples were dried on the thin-layer chromatography plate, sprayed with a tritium intensifying spray (Enhance, Sigma, Dorset, UK), and subjected to autoradiography. Large PC and minor LPC bands were seen clearly on the autoradiograph. These aligned perfectly with the stained PC and LPC standards. The concentration of LPC was measured densitometrically from the autoradiographs and expressed graphically as arbitrary optical density units per milligram of protein.
Apoptotic cell death assay
TUNEL assays were performed after the cells were fixed in 2.5% gluteraldehyde for 30 min at 25°C and washed 3× in PBS. Cells were permeabilized with 0.1% Triton X-100 for 15 min. After several washes with PBS, terminal deoxynucleotidyl transferase solution containing fluorescein-conjugated dUTP (Roche, West Sussex, UK) was added to the cells for 1.5 h in a 37°C humidified incubator. Cells were washed an additional 5× with PBS and were counterstained with 1% propidium iodide for 2 min at 25°C. After staining, cells were examined under an inverted fluorescence microscope. The percentage of apoptotic nuclei is expressed as a percentage of total nuclei by scoring at least 150 cells 3 per view. We counted 3-6 random fields per well of cells.
Data are expressed as means ± SD. ANOVA was performed for each group of treatments and statistical significance was assumed when P < 0.05.
Effect of Ucn LPC and BEL on cardiac myocyte survival
Cells were either untreated (control), treated with LPC (10 −6 mol/L) alone or with LPC in the presence of Ucn (10 −8 mol/L) or BEL (10 −6 mol/L), or in the presence of LPC, Ucn, and BEL, and the extent of apoptotic cell death was measured. Cells were also untreated or exposed to simulated ischemia for 4 h followed by reperfusion for 24 h. Other groups of cells were exposed to ischemia/reperfusion but in the presence of Ucn (10 −8 mol/L) alone, BEL alone (10 −6 mol/L), or a combination of Ucn plus BEL.
Animal model
Hearts from anesthetized male Sprague-Dawley rats were perfused by the non-recirculating Langendorff technique as described previously (18, 19) .
Treatment protocols
Isolated hearts were randomly divided into six groups (A-F) of at least six hearts each. Group A (ischemia/reperfused control group) was exposed to 30 min of regional ischemia and 2 h of reperfusion. In Groups B and C, Ucn (10 −8 mol/L) or BEL (10 −6 mol/L), respectively, were aerobically infused for 1 h, followed by regional ischemia followed by 2 h of reperfusion, according to the same protocol as in Group A. In Group D, hearts were aerobically perfused for 5 min with the addition to the perfusate of LPC (10 −6 mol/L) and subsequently were exposed to 30 min ischemia and 2 h reperfusion. In Groups E and F, Ucn (10
respectively, were aerobically infused for 1 h, prior to infusion of LPC for 5 min followed by ischemia and 2 h of reperfusion, according to the same protocol.
Regional ischemia
The left coronary artery of isolated hearts was surgically occluded for 30 min and subsequently reperfused for 2 h as described previously (18) .
Infarct size measurement
Measurement of risk area and infarct size was performed by triphenyltetrazolium chloride (TTC) staining as described previously (19) . TTC stains all living tissue brick red, leaving the infracted area unstained (white). LV infarct zone was determined by computerized planimetry and expressed as the percentage of infracted area within the myocardium at risk. Color enhancement was used to accentuate the differences between areas.
Left ventricular Pressure
To obtain an isovolumetrically beating preparation, a latex balloon filled with saline, connected by a catheter to a Statham transducer (P 23 XL), was inserted into the left ventricle through an atriotomy and secured by a suture around the atrioventricular groove. The balloon was inflated to provide an end-diastolic pressure <1.0 mm Hg (20) . The hemodynamics of the ex vivo hearts could then be monitored throughout the treatment protocols.
RESULTS
Affymetrix gene chip data
We found a 2.5-fold decrease in iPLA 2 transcript levels on the gene chip probed with labeled antisense RNA derived from Ucn-treated myocytes, when compared with the controls. The transcript levels of a cytosolic phospholipase cPLA and other phospholipases, PLC and PLD, which were also present on the chip, were unaltered with Ucn treatment.
iPLA 2 mRNA and protein levels are attenuated by Ucn
RT-PCR was performed on RNA from cardiac myocytes subjected to a 24 h exposure to Ucn. A single band of the predicted size for iPLA 2 was seen in PCR reactions from RNA derived from both control and Ucn treated cells. The intensity of this band was ~3.2-fold lower (n=3 observations) for Ucn-treated cells compared with controls. In a parallel experiment, rat cyclophilin levels showed no difference between control and Ucn-treated cells (Fig. 1a) . In contrast, we have previously observed that the transcript levels of a K ATP channel isoform, Kir6.1, was increased two-fold in cells treated with Ucn, compared with controls (14) . RNA slot blot results confirmed those of RT-PCR. The intensity of the signal from the RNA slot probed with labeled iPLA 2 cDNA was lower 2.8-fold (n=3 observations) in Ucn-treated cells compared with untreated cells. The housekeeping gene cyclophilin showed no differences in intensity between control and Ucn treated cells. (Fig. 1a) .
Using a specific iPLA 2 antibody, the protein levels for iPLA 2 reflect that of the mRNA levels. We observed 2.2-fold less (n=3 observations) protein in cells treated with Ucn compared with control cells. No differences were seen with an antibody specific for actin (Fig. 1a) .
A time course of Ucn treatment was also performed on primary myocytes to follow the fate of iPLA 2 protein levels over a 24 h period. Lower levels of enzyme protein were detectable after 8 h of Ucn exposure. These levels progressively decreased with further exposure to Ucn (Fig. 1b) .
IPLA 2 protein levels are lowered by ischemia and a 24 h reperfusion period. This effect can be abrogated by a CRH receptor antagonist
The effect of ischemia and reperfusion on the protein expression of iPLA 2 was investigated. Both exposure to 4 h ischemia, either alone or followed by 24 h of reperfusion, lowered the levels of iPLA 2 . When the CRH receptor antagonist α-helical CRH was applied to cells before exposure to ischemia and reperfusion, the reduction in the iPLA 2 protein levels was reversed (Fig. 1c) . This finding suggests that the lower iPLA 2 levels are caused by Ucn being released during ischemia/reperfusion and binding to its cardiac receptor.
Cardiac myocyte LPC concentrations are lowered by Ucn and a specific iPLA 2 enzyme inhibitor
To test whether the lower levels of iPLA 2 produced by Ucn treatment had a functional effect, we measured the levels of LPC, which is a metabolite of this enzyme. Pre-treatment of cardiac myocytes for 24 h with Ucn caused a significant 30% decrease in the concentration of LPC generated compared with control cells. This means that Ucn lowers LPC below basal values. This mechanism is probably due to lower amounts of iPLA 2 enzyme being present. A similar but even greater effect (50% reduction in LPC concentration) can be seen by a 24 h pre-treatment with the specific iPLA 2 inhibitor, BEL (Fig. 2a) . When cardiac myocytes were exposed to ischemia or ischemia/reperfusion, there was a large increase in LPC concentration compared with untreated cells. This increase was significantly lowered by a pre-treatment with Ucn (Fig.  2a) .
The effect of LPC alone and in combination with Ucn and BEL on myocyte survival
Interestingly, exogenously applied LPC is highly toxic to our primary myocyte preparations, causing a large (2.5-fold) increase in apoptotic cell death, compared with controls (Fig. 2b) . When either Ucn or BEL is applied to myocytes together with LPC, the toxic effect of LPC is reversed, close to control values. Moreover, a combination of both Ucn and BEL did not reverse further the cytotoxic effect of LPC (Fig. 2b) .
The effect of ischemia/reperfusion on cell death in the presence of Ucn and BEL
As expected, Ucn, when present during ischemia/reperfusion, is cardioprotective compared with cells exposed to ischemia/reperfusion alone. Furthermore, the selective iPLA 2 inhibitor BEL, is also cardioprotective. Both protective agents have a very similar protective potency. Again, when applied together during ischemia/reperfusion, their protective effects are not additive. Instead, the cardioprotection afforded by Ucn and BEL in combination is equivalent to that produced by either agent alone (Fig. 2c) .
Infarct size assessment following LPC infusion with and without pre-treatment with Ucn and BEL
To extend our studies to the intact heart, we examined the effect of LPC during ischemia/reperfusion of whole hearts ex vivo. Pretreatement with both Ucn or BEL significantly reduced infarct size compared with ischemia/reperfusion alone (Fig. 2d) . Fig. 2h is a representative picture of our infarcted hearts comparing ischemia/reperfusion in the presence and absence of Ucn. Pre-ischemic infusion of LPC produced a significant enlargement of the infarcted area, compared with control hearts exposed to ischemia/reperfusion (Fig. 2d) . A pretreatment with either Ucn or BEL, prior to infusion of LPC, significantly reduced the extent of infarct size compared with ischemia/reperfused hearts exposed to LPC alone. This protection was similar to that seen with Ucn and BEL alone during ischemia/reperfusion (Fig. 2d) .
Hemodymamics of the ischemic/reperfused rat heart
Left ventricular end-diastolic pressure (LVEDP) and left ventricular systolic pressure (LSVP) were also measured in the different treatment groups. In ischemic/reperfused control hearts, there was a constant developed pressure of 105.7 +/− 9.8 mm Hg, with no change in LEVDP during stabilization and aerobic perfusion (Fig. 2e) . Abolition of coronary flow caused a rapid augmentation in LVEDP, which started to rise 7 min after ischemia, progressively increased during the ischemic phase (31.7 +/− 4.8 mm Hg at the end of ischemia), and maintained values >50 mm Hg throughout reperfusion (Fig. 2e) . Administration of Ucn or BEL, during aerobic reperfusion, had no effect on either the hemodynamics (Fig. 2f, g ) or coronary flow (data not shown). However, infusion with either Ucn or BEL significantly reduced the progressive rise in LVEDP during ischemia (14.3 +/− 4.4 and 16.5 +/− 3.6 mm Hg, respectively, after 30 min ischemia vs. ischemia/reperfusion control (Fig. 2f, g ) and in both cases recovery in LVEDP at the end of reperfusion was complete (Fig. 2f, g ). In addition Ucn and BEL infusion produced a rapid recovery in LVSP, which started early during reperfusion (86.0 +/− 6.5 and 80.4 +/− 8.8 mm Hg, respectively, vs. ischemia/reperfusion control), which was near complete by the end of reperfusion (Fig. 2f, g ).
DISCUSSION
Here we have demonstrated for the first time, using microarray technology, that expression of a specific calcium-independent phospholipase A 2 enzyme (iPLA 2 ) is reduced in rat primary neonatal cardiac myocytes exposed to the cardioprotective agent Ucn. From the gene chip data, expression of other phospholipases, PLC and PLD, and other members of the PLA 2 family, specifically cPLA 2 , did not alter after Ucn treatment. Specific decreases in mRNA and enzyme protein of iPLA 2 were confirmed by RT-PCR, RNA slot blots, and Western blotting (Fig. 1a) . iPLA 2 protein levels decreased in a time-dependent manner after exposure to Ucn, up to 16-24 h (Fig. 1b) . Moreover, the Ucn receptor antagonist α-helical CRH abolished the decrease in iPLA 2 protein caused by simulated ischemia/reperfusion extending over a similar time period to that of Ucn treatment, suggesting that Ucn, induced by ischemia/reperfusion, is responsible for the decrease in iPLA 2 protein (Fig. 1c) .
iPLA 2 represents ~80% of the total PLA 2 activity in the myocardium (20) . The catabolic products of this enzyme include free fatty acids, AA, and LPC (15) . Although under normal conditions, iPLA 2 produces small amounts of LPC, during the early phase of ischemia and before endogenous Ucn has been released, to regulate iPLA 2 synthesis, there is a rapid increase in intracellular LPC, which correlates with an increase in iPLA 2 activity (15, 17) . Indeed, a 60% increase in LPC has been demonstrated within 8 min of ischemia (21) . When applied exogenously to cardiac myocytes, LPC produces cell death together with the mechanical and metabolic damage calcium overload and calcium efflux, characteristic of ischemia/reperfusion injury (15, 22) . Similarly, in our experiments exogenously applied LPC induced myocyte apoptosis. Therefore, LPC, one product of iPLA 2 activity, is an important mediator of ischemia/reperfusion-induced injury and this injury can be reversed by Ucn (Fig. 2b ).
Bromoenol lactone (BEL) is a specific and irreversible inhibitor of iPLA 2 activity and, like Ucn, reduces LPC concentration and protects cardiac myocytes from LPC-induced cell death (Fig. 2b ) and the effects of simulated ischemia/reperfusion injury (Fig. 2c) . This confirms the importance of the iPLA 2 isoform in LPC generation and its importance in ischemia/reperfusion injury. Inhibition of other isoforms also found in the heart, for example cPLA 2 with its specific antagonist AACOCF 3 , is not cardioprotective (15) . Like BEL, Ucn also reduces intracellular LPC (Fig. 2a) , and very interestingly, significantly lowers the highly elevated LPC concentration produced by ischemia and ischemia/reperfusion (Fig. 2a) . Thus, Ucn may prevent myocyte cell death by lowering LPC levels induced by ischemia/reperfusion (Fig. 2b, c) . However, Ucn, unlike BEL, acts not by inhibiting the catalytic activity of iPLA 2 but by reducing the levels of the enzyme protein. This probably explains why lower amounts of LPC are generated in the presence of the blocker compared with Ucn, which only partially lowers the concentration of the enzyme. Nevertheless both Ucn and BEL protect cardiac myocytes against injury caused by LPC and ischemia/reperfusion to a similar degree (Fig. 2b, c) .
Furthermore, when the two agents are given together during ischemia/reperfusion, no additive protective effect is seen suggesting that they may, at least in part, be working via a common mechanism involving inhibition/down-regulation of iPLA 2 and lowering LPC concentration (Fig.   2b, c) . Interestingly, when cardiac myocytes were pretreated with Ucn and subsequently treated with LPC, the cells were still protected from apoptosis.
This finding is somewhat surprising because reducing the levels of iPLA 2 protein should have no effect on the down-stream cardiotoxic properties of exogenous LPC. However, it has been demonstrated that LPC can activate iPLA 2 directly and thereby further increase its own concentration (23) , which suggests a mechanism for the effects we observe.
We have extended this study to the whole heart ex vivo. Again, we see that LPC is damaging in this model, causing a significantly greater infarct size during ischemia than ischemia alone. Furthermore, in agreement with our in vitro study, both Ucn and BEL, when added prior to ischemia or when added prior to LPC and ischemia, reduce infarct size to a level below that observed either with ischemia alone (Fig. 2h) or with exogenously applied LPC during ischemia (Fig. 2d, h ). Thus we now have in vitro and ex vivo models whereby Ucn provides cardioprotection from the damaging effects of ischemia and LPC.
Furthermore, we found that both Ucn and BEL significantly reduced the rise in LVEDP produced by ischemia and by the end of reperfusion recovery in both LVEDP and LVSP was near complete (Fig. 2 e-g ). Thus, both compounds, in addition to protecting the heart from increased infarct size caused by ischemia and reperfusion, also significantly enhance developed pressure with almost complete normalization of both LVEDP and LVSP by the end of the reperfusion phase when compared with the effects of ischemia and reperfusion alone.
The mechanism of action of LPC is unknown. However, LPC has been shown to modulate the activity of several ion channels and therefore produce rapid electrophysiological changes. In particular arrhythmias are produced by alterations of sodium channel current peak amplitude and gating properties (24) (25) (26) (27) , and the time course of LPC generation in ischemic myocardium parallels the time kinetics of early ischemic ventricular arrhythmias (28, 29) . Other studies have shown that LPC and other lysophospholipids can also directly modulate the activity of potassium channels (30, 31) . These metabolites have been shown to inhibit opening of K ATP channels (32) , which in heart have been extensively implicated in myocardial preconditioning and cardioprotection (33) (34) (35) . This finding is of particular interest because we have shown that Ucn induces both a decrease in iPLA 2 and LPC levels but increases the Kir6.1 isoform of ATPsensitive, inwardly rectifying potassium channels (14) .
Hence, the decrease in iPLA 2 and the increase in Kir6.1 may work together to modulate protection. We have shown previously that both the p42/p44 MAPK and the protein kinase B/Akt pathways are essential for protection by Ucn (6, 8, 9) . The increase in Kir6.1 and the decrease in iPLA 2 induced by Ucn are both blocked by inhibiting either of these pathways (unpublished data), which suggests that both these pathways are involved in transducing the Ucn signal to its target genes.
Thus, we have shown for the first time that Ucn, a novel cardioprotective agent, reduces the level of a specific enzyme iPLA 2 and its toxic metabolite LPC. Moreover, we have clearly demonstrated that reduction of the iPLA 2 pool produced by Ucn is cardioprotective both in vitro and ex vivo. Furthermore, these data suggest that CRH-R2 agonists, and/or iPLA 2 antagonists, may be useful therapies for minimizing cell loss and cardiac dysfunction following ischemia/reperfusion injury. 2 and actin in rat primary neonatal cardiac myocytes, as determined by Western blotting. c) Western blotting of iPLA 2 protein levels in rat primary neonatal cardiac myocytes exposed to 4 h simulated ischaemia (I) followed by 24 h reperfusion (I/R) alone, or in the presence of the Ucn antagonist α-helical CRH.
